JPRN-jRCT2080221534未知2 期
A phase IIa, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthma
Kyowa Hakko Kirin Co., Ltd.0 个研究点目标入组 100 人开始时间: 2011年8月8日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Uncontrolled asthma requiring medium-dose or high-dose ICS plus LABA
- •- History of => 2 but =< 6 documented asthma exacerbations in the 12 months that required use of a systemic corticosteroid burst
排除标准
- 未提供
研究者
相似试验
招募中
不适用
A study to evaluate the efficacy and safety of KHK4563 in adults with uncontrolled, suspected eosinophilic asthmaDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0000178JEIL-KIRIN PHARMACEUTICAL INC.100
进行中（未招募）
1 期
A Phase II, double blind, placebo controlled, dose-ranging study in patients with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.Postherpetic neuralgiaMedDRA version: 7.1 Level: LLT Classification code 10019979EUCTR2005-005863-26-GBTakeda Global Research & Development Centre (Europe) Ltd
进行中（未招募）
不适用
A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.Postherpetic neuralgiaMedDRA version: 7.1Level: LLTClassification code 10019979EUCTR2005-005863-26-DETakeda Europe R&D Centre Ltd400
进行中（未招募）
不适用
A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.EUCTR2005-005863-26-NLTakeda Europe R&D Centre Ltd400
进行中（未招募）
不适用
A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-583, compared with placebo.Postherpetic neuralgiaMedDRA version: 7.1Level: LLTClassification code 10019979EUCTR2005-005863-26-CZTakeda Europe R&D Centre Ltd400